Tin tức & Cập nhật
Xem bài viết Multidisciplinary
Xem
Chỉ hiển thị Multimedia

Semaglutide 2.4 mg gets US FDA approval for MASH
01 Sep 2025
bởiChristina Lau
Subcutaneous (SC) semaglutide 2.4 mg QW is recently granted accelerated approval by the US FDA for treatment of metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.








